Annovis Bio (ANVS) Stock Price, News & Analysis

Company Overview

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Key Stats

• Today's Range: $2.04 to $2.58
• 50-Day Range: $1.21 to $2.42
• 52-Week Range: $1.11 to $17.88
• Volume: 1.43 million shs
• Average Volume: 718,497 shs
• Market Capitalization: $47.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.75
• Consensus Rating: Buy

Annovis Bio Stock Analysis - MarketRank™

Annovis Bio scored higher than 32% of companies evaluated by MarketBeat, and ranked 789th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Annovis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Annovis Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Annovis Bio are expected to grow in the coming year, from ($2.19) to ($1.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Annovis Bio is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Annovis Bio is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.34% of the float of Annovis Bio has been sold short.

Short Interest Ratio / Days to Cover

Annovis Bio has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Annovis Bio has recently increased by 0.51%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Annovis Bio does not currently pay a dividend.

Dividend Growth

Annovis Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

20.34% of the float of Annovis Bio has been sold short.

Short Interest Ratio / Days to Cover

Annovis Bio has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Annovis Bio has recently increased by 0.51%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for ANVS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Annovis Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.80% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.83% of the stock of Annovis Bio is held by institutions.

ANVS Stock Analysis - Frequently Asked Questions

How have ANVS shares performed this year?

Annovis Bio's stock was trading at $5.03 at the beginning of the year. Since then, ANVS stock has decreased by 51.9% and is now trading at $2.42.
View the best growth stocks for 2025 here.

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.15.

When did Annovis Bio IPO?

Annovis Bio (ANVS) raised $10 million in an IPO on Wednesday, January 29th 2020. The company issued 1,400,000 shares at $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO.

Who are Annovis Bio's major shareholders?

Top institutional shareholders of Annovis Bio include Warberg Asset Management LLC (0.27%), Lokken Investment Group LLC (0.21%) and Simplex Trading LLC.
View institutional ownership trends.

How do I buy shares of Annovis Bio?

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ANVS
• CIK: 1477845
• Web: www.annovisbio.com
• Phone: 610-727-3913
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $34.75
• High Stock Price Target: $67.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +1,336.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -311.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.73) per share
• Price / Book: -3.32

Miscellaneous

• Outstanding Shares: 19,486,000
• Free Float: 9,638,000
• Market Cap: $47.16 million
• Optionable: Optionable
• Beta: 1.46